Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VHB937 versus placebo in adults with amyotrophic lateral sclerosis
NL-OMON59105Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VHB937 in amyotrophic lateral sclerosis (ALS) (4 arms), sponsored by Novartis. Primary endpoint: Combined Assessment of Function and Survival. Started Feb 2025; status: active, not recruiting.
02
Drugs
VHB937
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON59105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59105.